EMA to Review Lundbeck Drug Deanxit After Serious Side Effects Reported
The European Medicines Agency will review Lundbeck's depression and anxiety drug Deanxit after reports of serious side effects.
Related stories
Bessent Says NVIDIA Board Must Respond Within 10 Days on Export Compliance
Treasury Secretary Scott Bessent said on Fox that NVIDIA’s board and outside counsel must answer within 10 days about the company’s compliance culture regarding export restrictions
M impact | REGULATION | Nov 15, 2026, 03:10 PM UTC
Bessent Says NVIDIA Board Must Answer on Export-Compliance Culture
Bessent said on Fox that NVIDIA’s board and outside counsel must answer within the next 10 days about the company’s compliance with export restrictions.
M impact | REGULATION | Nov 15, 2026, 03:10 PM UTC
Estonia to Close Russian Border Crossings From December 1
M impact | REGULATION | Nov 15, 2026, 03:05 PM UTC
FDA Declines to Approve Summit Lung Cancer Drug After Trial Misses Survival Goal
The FDA declined to approve Summit Therapeutics' lung cancer drug after its trial missed a key survival goal.
M impact | REGULATION | Nov 15, 2026, 01:20 PM UTC
US Judge Again Blocks Trump Plan to Renovate DC Golf Course
A US judge temporarily blocked the plan, according to the headline and available report text.
L impact | REGULATION | Nov 15, 2026, 02:35 AM UTC
UK to Expand Jobs Guarantee Scheme for Young People
The British government will expand its jobs guarantee scheme for young people.
L impact | REGULATION | Nov 14, 2026, 10:30 PM UTC